Dynamics of soil phosphorus measured by ammonium lactate extraction as a function of the soil phosphorus balance and soil properties

A sustainable supply of phosphorus (P) to agricultural soils should maintain soil fertility without jeopardizing the environment. This study analyzed the change in the soil P as a function of the net soil P mass balance, i.e. the input minus removal by the harvested crop. The P available for crops was estimated by the P extracted by ammonium lactate at pH 3.75 (P-AL). First, laboratory and pot-trial data showed that the net change in soil P-AL was only 68% of the change in total soil P, either when P had been added to soil or when P had been mined by plants for 1–2 years, indicating removal to or release from the non-extractable pool depending on the balance. Secondly, data were collated from 33 field trials in Europe with a wide range of cumulative soil P balances (−1200 to +2500 kg P ha−1) in time spans ranging from 3 to 51 years. The average change in P-AL across the negative and positive balance was only 27% (95% confidence interval 25–30%) of the net balance. The change in P-AL was larger as the net balance increased and as the initial P-AL decreased. The slope of the change versus the balance was smaller as time increased and initial P-AL decreased. The other soil characteristics did not affect these changes, and the model developed was not different for negative or positive P balances. Our results suggest that a steady state P-AL concentration at optimal P supply for crops is obtained at a net P balance of about 1–10 kg P ha−1. The P mass balance of a 51 year-old trial showed that the aqua regia soluble P of the 0–90 cm layer accounted for only 64% of the net P balances at the surface. This still incomplete P balance could be related to upward P transport by plant uptake from > 90 cm soil layers, lateral P movement in the field, and changes in the soil P fraction that could not be extracted with aqua regia. This study quantified the long-term dynamics of P-AL, which is useful for agronomic and environmental purposes and policy, and pointed out the importance of non-extractable P and vertical P movement

A comparison of soil tests for available phosphorus in long-term field experiments in Europe

Summary. Most soil tests for available phosphorus (P) perform rather poorly in predicting crop response. This study was set up to compare different established soil tests in their capacity to predict crop response across contrasting types of soil. Soil samples from long‐term field experiments, the oldest >100 years old, were collected in five European countries. The total number of soil samples (n = 218), which differed in cropping and P treatment, and originated from 11 different soil types, were analysed with five tests: ammonium oxalate (Ox), ammonium lactate (AL), Olsen P, 0.01 m CaCl2 and the diffusive gradient in thin film (DGT). The first three tests denote available P quantity (Q), whereas the last two indicate P intensity (I) of the soil solution. All five tests were positively related to the crop yield data (n = 317). The Q‐tests generally outperformed I‐tests when evaluated with goodness of fit in Mitscherlich models, but critical P values of the I‐tests varied the least among different types of soil. No test was clearly superior to the others, except for the oxalate extraction, which was generally poor. The combination of Q‐ and I‐tests performed slightly better for predicting crop yield than any single soil P test. This Q + I analysis explains why recent successes with I‐tests (e.g. DGT) were found for soils with larger P sorption than for those in the present study. This systematic evaluation of soil tests using a unique compilation of established field trials provides critical soil P values that are valid across Europe. Highlights. We compared soil P tests for predicting crop response across contrasting soil types. No test was clearly superior to the others except for the oxalate extraction, which was generally poor. This study suggests that intensity tests do not perform markedly better than quantity tests. The evaluation of soil P tests on this unique dataset provided critical soil P values across Europe

Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction

Background: Current fibrinolytic therapies fail to achieve optimum reperfusion in many patients. Low-molecular-weight heparins and platelet glycoprotein IIb/IIIa inhibitors have shown the potential to improve pharmacological reperfusion therapy. We did a randomised, open-label trial to compare the efficacy and safety of tenecteplase plus enoxaparin or abciximab, with that of tenecteplase plus weight-adjusted unfractionated heparin in patients with acute myocardial infarction. Methods: 6095 patients with acute myocardial infarction of less than 6 h were randomly assigned one of three regimens: full-dose tenecteplase and enoxaparin for a maximum of 7 days (enoxaparin group; n=2040), half-dose tenecteplase with weight-adjusted low-dose unfractionated heparin and a 12-h infusion of abciximab (abciximab group; n=2017), or full-dose tenecteplase with weight-adjusted unfractionated heparin for 48 h (unfractionated heparin group; n=2038). The primary endpoints were the composites of 30-day mortality, in-hospital reinfarction, or in-hospital refractory ischaemia (efficacy endpoint), and the above endpoint plus in-hospital intracranial haemorrhage or in-hospital major bleeding complications (efficacy plus safety endpoint). Analysis was by intention to treat. Findings: There were significantly fewer efficacy endpoints in the enoxaparin and abciximab groups than in the unfractionated heparin group: 233/2037 (11.4%) versus 315/2038 (15.4%; relative risk 0.74 [95% CI 0.63-0.87], p=0.0002) for enoxaparin, and 223/2017 (11.1%) versus 315/2038 (15.4%; 0.72 [0.61-0.84], p<0.0001) for abciximab. The same was true for the efficacy plus safety endpoint: 280/2037 (13.7%) versus 347/2036 (17.0%; 0.81 [0.70-0.93], p=0.0037) for enoxaparin, and 287/2016 (14.2%) versus 347/2036 (17.0%; 0.84 [0.72-0.96], p=0.01416) for abciximab. Interpretation: The tenecteplase plus enoxaparin or abciximab regimens studied here reduce the frequency of ischaemic complications of an acute myocardial infarction. In light of its ease of administration, tenecteplase plus enoxaparin seems to be an attractive alternative reperfusion regimen that warrants further study